User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 8 results.
    • Speech
    Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.
    Van den Eynde, Marc[UCL] Huyghe, Nicolas De Cuyper, Astrid[UCL] Sinapi, Isabelle Ferrier, Marie Gilet, Mélanie Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jerome Carrasco, Javier (2021) 2021 Gastrointestinal Cancers Symposium —
    • Speech
    Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.
    Van den Eynde, Marc[UCL] Castella, Marie-Laure[UCL] Machiels, Jean-Pascal[UCL] Humblet, Yves[UCL] Canon, Jean-Luc Houbiers, Ghislain Demolin, Gauthier D'Hondt, Lionel[UCL] Coche, Jean-Charles Van Daele, Daniel Delaunoit, Thierry Goeminne, Jean-Charles Benuiga, Gabriella Pairet, Géraldine Sempoux, Christine[UCL] Mourin, Anne[UCL] van Maalen, Aline[UCL] Carrasco, Javier (2015) 2015 ASCO GI — (United States) San Francisco, CA
    • Speech
    635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
    Van den Eynde, Marc[UCL] Huyghe, Nicolas[UCL] Sinapi, Isabelle De Cuyper, Astrid[UCL] Verstraelen, Eleonore Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Papier, Matthias Bedognetti, Davide van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jerôme Carrasco, Javier (2023) ESMO Congress 2023 — (Spain) Madrid
    • Speech
    Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Huyghe, Nicolas[UCL] De Cuyper, Astrid[UCL] Sinapi, Isabelle Vempalli, Fazulur Rehaman Rinchai, Darawan Beyaert, Simon[UCL] Verstraelen, Eleonore Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Gilet, Mélanie Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Mlecnik, Bernhard Carrasco, Javier Galon, Jerome Bedognetti, Davide Van den Eynde, Marc[UCL] (2022) 2022 ASCO Annual Meeting I —
    • Speech
    2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
    Huyghe, Nicolas[UCL] Benidovskaya, Elena[UCL] Masoodi, Tariq Carrasco, Javier De Cuyper, Astrid[UCL] Sinapi, Isabelle Vempalli, Fazulur Verstraelen, Eleonore Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Papier, M. Bedognetti, Davide van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jérôme Van den Eynde, Marc[UCL] (2023) ESMO Congress 2023 — (Spain) Madrid
    • Speech
    Homogeneity of pathological response (PR) and histopathological growth pattern (HGP) in resected colorectal liver metastases (CRLM) are associated with favorable survival outcome after surgery.
    Baldin, Paméla[UCL] Beniuga, Gabriella Carrasco, Javier De Cuyper, Astrid[UCL] Sinapi, Isabelle Hubert, Catherine[UCL] Navez, Benoît[UCL] Castella, Marie-Laure Van Maanen, Aline[UCL] Mlecnik, Bernhard Galon, Jerome Jouret-Mourin, Anna[UCL] Van den Eynde, Marc[UCL] (2022) 2022 ASCO Annual Meeting I —
    • Journal article
    Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
    Baldin, Paméla[UCL] Carrasco, Javier Beniuga, Gabriela Mourin, Anne[UCL] Demolin, Gauthier Roland, Sandrine D'Hondt, Lionel[UCL] Vergauwe, Philippe Van Daele, Daniel Mailleux, Marie Sinapi, Isabelle De Cuyper, Astrid[UCL] Blétard, Noëlla Massart, Brigitte Delos, Monique[UCL] Castella, Marie-Laure[UCL] van Maanen, Aline[UCL] Van den Eynde, Marc[UCL] (2022) Cancers — Vol. 14, no. 5, p. 1183 [1-16] (2022)
    • Speech
    120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
    Benidovskaya, Elena[UCL] Huyghe, Nicolas[UCL] Carrasco, Javier De Cuyper, Astrid[UCL] Sinapi, Isabelle Verstraelen, Eléonore[UCL] Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Papier, M. Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jérôme Van den Eynde, Marc[UCL] (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich